Alvogen and Natco Secure First-to-File Status on Generic Version Of Tamiflu®

- 180-day marketing exclusivity expected

- U.S. brand sales in excess of US$1 billion

- Complements a fast growing U.S. pipeline of over 70 drugs

PARSIPPANY, N.J.--(BUSINESS WIRE)-- Alvogen, the US-based pharmaceutical company, today announced that its India-based partner, Natco Pharma Limited, has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) for the generic version of Tamiflu® (oseltamivir phosphate). Both Natco and Alvogen believe it is the first substantially completed ANDA filing containing a Paragraph IV certification and expect to qualify for 180 days of marketing exclusivity upon final FDA approval. Oseltamivir phosphate capsules are used in the treatment of bird and swine flu infections and sold by Hoffman – La Roche under the brand name Tamiflu®. According to IMS Health in 2009, Tamiflu® had U.S. sales in excess of US$1 billion.

“The ANDA filing of oseltamivir represents a significant milestone for Alvogen in the U.S. market,” said Robert Wessman, Executive Chairman of Alvogen. “We are confident that the filing will qualify for 180-day exclusivity upon FDA approval and we expect the product to offer significant value to our customers and patients. While we are steadily growing our product pipeline through partnerships, our internal capabilities still form an important cornerstone of our development strategy. We will continue our journey of growth and expansion as we move towards our goal of positioning Alvogen among leading global generics companies.”

A fast growing product portfolio - Alvogen has built a dynamic product pipeline of more than 200 products, of which 70 are for the U.S. market. Currently, Alvogen has over 200 marketing authorizations pending regulatory approval, representing US$21 billion in annual global sales, according to IMS Health. The company aims to submit over 100 marketing authorizations in the U.S. and Europe in 2011 and launch over 100 products in its markets.

Offices around the world – Alvogen continues to grow its marketing network and has identified over 20 emerging markets in Europe, Asia and Latin America as its priorities for entry. Through a highly refined selection process, Alvogen targets complex generic products that have the potential for reduced market competition. The company has built an industry-leading internal development capability and a strong and effective network of industry partners that continue to support Alvogen’s ambitious growth plans.

Get more information on Alvogen at www.alvogen.com

Alvogen is a multinational, privately-owned pharmaceuticals company, focused on complex generic pharmaceutical products. The company is committed to building the next-generation generics company through the strategic selection of products, partners and markets, and the utilization of an effective consolidated global supply chain. Robert Wessman, former CEO of Actavis Group, one of the largest generic companies in the world, is the Executive Chairman and will lead Alvogen’s global expansion.

With more than 200 pharmaceutical products in development and registration, a further 100 or more product launches are expected in 2011. The group’s product portfolio consists of a broad range of leading molecules for the treatment of conditions in the fields of oncology, cardiology, respiratory, neurology and gastroenterology. Alvogen has first-class regulatory, development and manufacturing capabilities in Asia, Europe and North America.

About Natco

Natco Pharma Limited is a specialty pharmaceutical company developing, manufacturing, and marketing pharmaceutical products. Natco is headquartered in Hyderabad, Andhra Pradesh, India. Natco has a leadership position in the Oncology segment in India. Apart from its branded generic business Natco is engaged in discovery research and development of novel drug delivery systems.



CONTACT:

Alvogen
Global Communications & Media Relations
Halldor Kristmannsson, +354 522 2900
[email protected]

KEYWORDS:   United States  Europe  North America  New Jersey

INDUSTRY KEYWORDS:   Health  Hospitals  Medical Devices  Pharmaceutical  FDA  Managed Care

MEDIA:

Logo
 Logo

Suggested Articles

While the failure might be a missed chance at revenue, it shouldn’t hurt Ibrance’s ability to rack up sales in the metastatic setting, one exec says.

Patients receiving Bavencio actually did worse than those who got placebo, increasing the risk of death by 31%.

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.